1 ACPS November 15, 2000 314.70 Update Nancy B. Sager, Associate Director Office of Pharmaceutical Science Center for Drug Evaluation & Research Food and.

Slides:

Advertisements

Similar presentations

U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDAs website for reference purposes only. It.

Advertisements

When is Excipient Reduced Testing Appropriate?

Arthur Fabian, PhD February 7, 2007 FDA Public Meeting Rockville MD.

ICH Q4B Regulatory Acceptance of Analytical Procedures and/or Acceptance Criteria (RAAPAC) Overview and Update Robert H. King, Sr. Office of Pharmaceutical.

Dissolution stability of a modified release product 32 nd MBSW May 19, 2009

"Determining the Regulatory Pathway to Market" Classification Heather S. Rosecrans Director, 510(k) Staff Office of Device Evaluation Center for Devices.

Anticounterfeiting of Solid Oral Dosage Forms Hemant N. Joshi, Ph.D., MBA Tara Innovations LLC Parsippany, NJ

Fundamentals of Regulatory Affairs eighth edition

Development of Guidance Documents Jennifer Scharpf, M. P. H

VALIDATION What is the new guidance?. What is a Compliance Policy Guide? Explain FDA policy on regulatory issues CGMP regulations and application commitments.

“Paperless Labeling Rule” Proposed Rule First Look January 2015.

Rapid Microbiology Methods A Regulatory Viewpoint Bryan S. Riley, Ph.D. U.S. Food and Drug Administration Center for Drug Evaluation and Research Office.

1 CFR CHAPTER I AND 1 CFR PART 51 REGULATORY UPDATE.

Development and Review Process of NDA, ANDA/AADA and OTC Dr. Basavaraj K. Nanjwade M. Pharm., Ph. D Associate Professor Department of Pharmaceutics KLE.

Cross-Labeling: Legal and Regulatory Issues David M. Fox Hogan & Hartson LLP th Street, NW Washington, DC

COMPARABILITY PROTOCOLS ACPS March 12-13, 2003 Stephen K. Moore, Ph.D. Chemistry Team Leader CDER/Office of New Drug Chemistry Co-Chair, Comparability.

CBER Managed Review Process Sheryl A. Kochman Deputy Director, DBA, OBRR, CBER September 15, 2009.

The FDA Landscape AdvaMed September 2008 Judith K. Meritz

Regulation of Generic Drugs Office of Generic Drugs Craig Kiester Regulatory Support Branch.

Classification of HLA Devices FDA Introduction & Background Sheryl A. Kochman CBER/OBRR/DBA.

Individual Bioequivalence Lawrence J. Lesko, Ph.D. Director Office of Clinical Pharmacology and Biopharmaceutics Advisory Committee for Pharmaceutical.

ONDQA Perspective on Post Approval Changes Eric P. Duffy, PhD Director, Division of Post-Market Evaluation, ONDQA, CDER, FDA Public Meeting: Supplements.

1 Revisions to 21 CFR Supplements and Other Changes to an Approved Application PhRMA Perspective FDA Public Meeting – 7 Feb 2007.

1 DRUG QUALITY SYSTEM FOR THE 21 ST CENTURY PQRI/FDA April CHANGES WITHOUT PRIOR APPROVAL AN FDA PERSPECTIVE Dennis M. Bensley, Jr., Ph.D. Center.

FDA’s Perspective Continued - Where We Are ?. GMP Task Groups.

Requirements for Standardized Study Data: Update on Guidance Ron Fitzmartin, PhD, MBA Data Standards Program Office of Strategic Programs Center for Drug.

What You Want to Know About Generic Drugs Generic Drugs: Safe. Effective. FDA-Approved.

DRAFT Guidance for Industry: Providing Regulatory Submissions in Electronic Format – Drug Establishment Registration and Drug Listing Denise Sánchez, J.D.,

Achieving and Demonstrating “Quality-by-Design” with Respect to Drug Release/dissolution Performance for Conventional or Immediate Release Solid Oral Dosage.

Center for Veterinary Medicine (CVM) RECALLS.  21 CFR 7.40 provides guidance on the policy, procedures, and industry responsibilities for recalls. 

Nonclinical Studies Subcommittee Advisory Committee for Pharmaceutical Science CMC Issues for Screening INDs Eric B. Sheinin, Ph.D. Acting Deputy Director.

Industry Perspective on Challenges for Product Developers - Drugs Christine Allison, M.S., RAC Associate Regulatory Consultant, Global Regulatory Affairs.

1 Supplements and Other Changes to an Approved Application By: Richard J. Stec Jr., Ph.D. February 7, 2007.

Ajaz S. Hussain, Ph.D. Deputy Director Office of Pharmaceutical Science, CDER, FDA ACPS Subcommittee on Manufacturing Science: Identification and Prioritization.

ICH V1 An FDA Update Min Chen, M.S., RPh Office of Drug Safety Center for Drug Evaluation and Research FDA January 21, 2003.

ICH V2 An FDA Update Susan Lu Office of Drug Safety Center for Drug Evaluation and Research FDA January 21, 2003.

1 Update on Nanotechnology Activities in CDER and FDA Keith O. Webber, Ph.D. Deputy Director OPS/CDER/FDA ACPS Meeting Tuesday, July 22, 2008.

1 Regulatory Aspects of Pharmaceutical Excipients PQRI Workshop Nick Buhay Acting Director Division of Manufacturing and Product Quality Office of Compliance.

1 FDA’s Framework for Reviewing Regulations Leslie Kux Acting Assistant Commissioner for Policy U.S. Food and Drug Administration March 10, 2011.

Proposal for End-of-Phase 2A (EOP2A) Meetings Advisory Committee for Pharmaceutical Sciences Clinical Pharmacology Subcommittee November 17-18, 2003 Lawrence.

Overview of FDA's Regulatory Framework for PET Drugs

1 Part 74 Material Control and Accounting (MC&A) Rulemaking Update NMMSS Users Annual Training Meeting Las Vegas, NV – May 20, 2010 Thomas Pham Material.

COMPARABILITY PROTOCOLUPDATE ADVISORY COMMITTEE FOR PHARMACEUTICAL SCIENCE Manufacturing Subcommittee July 20-21, 2004 Stephen Moore, Ph.D. Chemistry Team.

Bioequivalence of Locally Acting Gastrointestinal Drugs: An Overview

Over-the-Counter Drug Products Over-the-Counter (OTC) drug products are those drugs that are available to consumers without a prescription. There.

REGULATION OF COMBINATION PRODUCTS Mark A. Heller Wilmer Cutler Pickering Hale and Dorr LLP MassMEDIC Combination Product Program, March 28, 2006.

Guidance Update: Average, Population, and Individual Approaches to Establishing Bioequivalence Mei-Ling Chen, Ph.D. Associate Director Office of Pharmaceutical.

Nanotechnology - USDA - 18 Nov 2002 REGULATORY CONSIDERATIONS FOR NANOTECHNOLOGY IN PUBLIC HEALTH FOOD AND DRUG ADMINISTRATION Norris E. Alderson, Ph.D.

Comparability Protocols Lore Fields MT(ASCP)SBB Consumer Safety Officer DBA/OBRR/CBER September 16, 2009.

1 Office of Pharmaceutical Science on Jon Clark FDA/CDER/OPS Associate Director for Policy Development.

Enforcement Litigation and Compliance Washington, DC December 9-10, 2015 Compliance Central with FDA Center Compliance Directors (Part I) Michael Roosevelt,

1 Drug Safety Oversight Board: Recent Activities FDA Science Board Advisory Committee Meeting March 31 st, 2006 Douglas C. Throckmorton, MD Deputy Director.

Update on Current FDA Labeling Initiatives Iris P. Masucci, PharmD, BCPS Center for Drug Evaluation and Research FDA November 16, 2006 Pediatric Advisory.

CEQA and the Delta Plan Presentation to Delta Stewardship Council February 24, 2011.

Comparability Protocols Nancy Sager Associate Director, QIS-Chemistry FDA/CDER/OPS.

U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.

Bioequivalence Criteria Research Plan Stella G. Machado, Ph.D. Office of Biostatistics and the Replicate Design Technical Committee Advisory Committee.

Lawrence X. Yu, Ph.D. Director for Science Office of Generic Drugs, OPS, CDER, FDA ACPS Meeting, ACPS Meeting, Oct. 22, 2003 Office of Generic Drugs Research.

Examining Drug Quality Regulation Douglas C. Throckmorton, MD Deputy Director Center for Drug Evaluation and Research Public Meeting on 21 CFR February,

COPYRIGHT ALL RIGHTS RESERVED. LEGAL DISCLOSURE. November 25, 2002 PRESENTATION TO: Public Hearing: FDA Regulation of Combination Products November.

DEPARTMENT OF HEALTH CENTER FOR BIOLOGICS AND HUMAN SERVICESEVALUATION and RESEARCH AND HUMAN SERVICES EVALUATION and RESEARCH Update on OCTGT Guidance.

Orally Inhaled and Nasal Drug Products (OINDP) Subcommittee Report to the Advisory Committee for Pharmaceutical Sciences Rockville, Maryland November 15,

DEPARTMENT OF HEALTH CENTER FOR BIOLOGICS AND HUMAN SERVICESEVALUATION and RESEARCH AND HUMAN SERVICES EVALUATION and RESEARCH Update on the Somatic Cell.

Guidance Development Merton V. Smith, Ph.D., J.D. Director International Programs and Product Standards Center for Veterinary Medicine, FDA.

Post-Notice of Compliance (NOC) Changes

Regulatory– Terms & Definitions רגולציה - מונחים והגדרות

FDA’s IDE Decisions and Communications

Quality System.

NRC’s LLW Regulatory Program: Update of Emerging Issues

TRTR Briefing September 2013

Presentation transcript:

1 ACPS November 15, Update Nancy B. Sager, Associate Director Office of Pharmaceutical Science Center for Drug Evaluation & Research Food and Drug Administration

2 Regulatory Approach CDER’s regulatory approach to post approval CMC changes is evolving 21 CFR (1985 rewrite) SU/PACs (early 90’s to present) FDAMA (1997) Implementation of FDAMA §116 (now) Next ?

3 21 CFR : Supplements and Other Changes to an Approved Application (1985 rewrite) “The applicant shall notify FDA about each change in each condition established in an approved application beyond variations provided for in the application” Provides a general listing of changes with reporting mechanisms

4 Scale Up/Post Approval Change - Guidance Documents Level of Changes Minor change Moderate change Major change Application / Compendial Tests In Vitro Dissolution / Release In Vivo Annual Report Changes Being Effected Supplement Prior Approval Supplement Tests Filing

5 FDA Modernization Act Section 116 (November 1997) Recognized the importance of the SU/PAC approach Amended the Food, Drug, and Cosmetic Act by adding Section 506A Required revision of Guidance was developed to document FDA’s current thinking on how to apply Section 506A

6 FDAMA Section 116 Reporting categories are based on the potential for the change to adversely affect the identity, strength, quality, purity, or potency of a product as they may relate to the safety or effectiveness of the drug product.

7 FDAMA Section 116: Reporting Categories Substantial potential –Prior approval supplements Moderate potential: –Supplement — changes being effected in 30 days (CBE-30) –Supplement — changes being effected (CBE-0) Minimal potential –Annual reports

8 FDAMA 116 Implementation Status Draft guidance published for public comment on June 28, 1999; comment period closed on Aug. 27, 1999; final guidance published Nov (30 comment letters, 1200 individual comments) Proposed regulation published for public comment on June 28, 1999; comment period closed on Sept. 13, 1999 (30 comment letters, 300 individual comments)

9 Changes to an Approved NDA or ANDA (Nov guidance) Modeled on SU/PACs Recommends reporting categories only Covers all dosage forms No recommendations on specific information that should be developed by the applicant to assess the effect of the change

10 FDAMA 116 Implementation Status The November 1999 guidance on Changes to an Approved NDA or ANDA represents FDA’s current thinking on how it will apply the requirements of section 506A of the Act for NDA and ANDA products.

11 FDAMA 116 Implementation Status (cont’d) Until the final regulation for § publishes, section 506A is the sole basis for FDA’s regulation of postapproval manufacturing changes for products approved in NDAs or ANDAs

12 FDAMA 116 Implementation Status (cont’d) The final rule for § has been drafted and is in the beginning stages of the clearance process (ETA = winter/spring) The guidance on Changes to an Approved NDA or ANDA is being revised to conform to § and will publish at the same time as the final rule.